AlphAIalphai — Financial news for AI agents
thestarphoenix.comAUG 31 min read$PMN

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

ProMIS Neurosciences Inc. (Nasdaq: PMN) said it will release its second-quarter 2026 financial results for the period ended June 30, 2026 and provide a business update on Aug. 13, 2026. The company will hold an investor conference call and webcast at 4:30 p.m. ET, with a replay available afterward on its website.

Original reporting
thestarphoenix.com
Published Aug 3, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 10:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$PMN
Neutral
medium confidence
Mentioned
$PMN
Relevance
5/10
alphai data visualization · based on thestarphoenix.com
Decision brief

The 30-second read

$PMNNeutralMed
01

Why it matters

The announcement primarily establishes a concrete event date and time for Q2 2026 results and a corporate update, which can drive short-term positioning and implied volatility.

02

Market read

This is a scheduled earnings and corporate-update catalyst for PMN, with potential volatility concentrated around the Aug. 13, 2026 call.

03

What to watch

Traders should focus on what the corporate update includes on Aug. 13 (e.g., trial progress, financing, partnerships), since that is the only potential source of surprise not provided here.

Relevance 5/10Novelty 5/10Timing: Aug. 13, 2026 pre/post-market positioning for Q2 results and corporate update call at 4:30 p.m. ET

Background

ProMIS Neurosciences is a clinical-stage biotech focused on antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases.

Company-level read

Ticker impact

$PMNNeutralMedium confidence
Context

ProMIS Neurosciences (PMN) announced it will report Q2 2026 financial results and corporate updates on Aug. 13, 2026 at 4:30 p.m. ET.

Expected impact

Likely volatility around Aug. 13, 2026 as traders position for the Q2 results and any corporate updates; direction depends on the yet-unprovided figures.

Evidence & confidence

The article discloses the timing of the results and webcast but provides no Q2 numbers, guidance, or new operational milestones.

Market effects

Sector

Adds another scheduled catalyst for clinical-stage neurodegeneration biotech sentiment, but no sector-wide policy or data is disclosed.

Regional

Minimal, as the event is company-specific with no macro/regional linkage stated.

Global

Low, since the release is a standard investor-relations update with no international regulatory or trial headline.

Counterpoint

What could challenge this read

Because the release contains no new financial or clinical specifics, the market may treat it as routine and price in little until the actual Q2 numbers are released.

Key entities

  • company
    ProMIS Neurosciences Inc.

    Clinical-stage biotechnology company developing antibody therapeutics and vaccines for neurodegenerative diseases.

  • ticker
    Nasdaq: PMN

    The company’s listed equity symbol referenced in the announcement.

Read at source← All news

Related articles

JUL 29
$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

rttnews.com7 min
JUL 28
$PMNMed

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data

Promis Neurosciences (NASDAQ:PMN) reported interim Phase 1b safety data for PMN310 in Alzheimer’s. As of July 22, there were no ARIA-E cases in the blinded safety population and no treatment-related serious adverse events. Total ARIA was 4.4% (mild, asymptomatic ARIA-H). Biomarkers showed declines in plasma p-tau217 and CSF MTBR-tau243. Dosing runs to Dec 2026; unblinding expected early 2027.

finance.yahoo.com5 min
JUL 28
$PMNMedAI 8/10

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - ProMI

ProMIS Neurosciences reported a blinded interim safety analysis of PMN310 in an early Alzheimer’s study with 136 patients. It said no ARIA-E cases occurred by the cutoff, total ARIA incidence was 4.4% and limited to mild, asymptomatic ARIA-H. No treatment-related serious adverse events or discontinuations were reported, including in APOE4 carriers. Unblinded 12-month topline results are expected in Q1 2027.

benzinga.com5 min
JUL 28
$PMNMedAI 8/10

Why is ProMIS Neurosciences stock surging today? By Investing.com

ProMIS Neurosciences (PMN) shares rose about 16% pre-open after the company reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310. In 136 patients, there were zero ARIA-E cases, 4.4% total ARIA incidence, and no treatment-related serious adverse events. Chardan started coverage with a Buy and $20 target.

investing.com4 min
JUL 28
$PMNMedAI 8/10

ProMIS Neurosciences Inc.: ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

ProMIS Neurosciences (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 in 136 Alzheimer’s patients. As of the cutoff, no ARIA-E occurred and total ARIA was 4.4% (mild, asymptomatic ARIA-H only). Early biomarker shifts in pTau217 and CSF MTBR-tau243 were reported. Unblinded 12-month topline data are expected in Q1 2027.

finanznachrichten.de5 min